Pruritus Therapeutic Market 2023 – Size, Industry Growth Rate, Top Trends, Major Players And Forecast To 2032 | Allergan PLC, Astellas Pharma Inc., Bristol-Myers Squibb Company, Cipla Inc., Eli Lilly and Company

Pruritus Therapeutic Market

The Pruritus Therapeutic Global Market Report 2023, provides comprehensive information on the pruritus therapeutic market across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Pruritus Therapeutic Market’s Growth:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

According to The Business Research Company’s esteemed Pruritus Therapeutic Global Market Report for the year 2023, the landscape of this market is poised for notable transformation and growth. The market size, which was recorded at $12.09 billion in 2022, is forecasted to witness a significant upswing, projecting to reach an impressive $13.10 billion by the year 2023. This upward trajectory is underpinned by a robust Compound Annual Growth Rate (CAGR) of 8.4%.

However, it is imperative to situate this positive outlook within the broader context of global economic dynamics. The ongoing Russia-Ukraine conflict has introduced complexities that have impeded the potential for a swift resurgence from the COVID-19 pandemic. This geopolitical strife has prompted the implementation of economic sanctions across multiple nations, contributing to a surge in commodity prices and instigating disruptions within global supply chains. These repercussions have, in turn, fueled inflationary pressures that resonate across a wide spectrum of goods and services, exerting an impact on various markets on a global scale. Notwithstanding these challenges, the global pruritus therapeutic market size is anticipated to ascend to a notable $17.98 billion by the year 2027, guided by a commendable CAGR of 8.2%. This forecast underscores the resilience of the pruritus therapeutic sector and its ability to navigate the intricate currents of the global economic landscape.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample_request?id=9925&type=smp

The pruritus therapeutic market is currently witnessing a prominent and pivotal trend, and that is the innovative strides made in product development. Leading corporations in this domain are dedicating their efforts to pioneering novel medications and therapies designed to address pruritus and its associated conditions. A striking example of this commitment to innovation was witnessed in August 2022 when Maruho Co., Ltd., a distinguished pharmaceutical company based in Japan, introduced the groundbreaking anti-IL-31 receptor, a humanized monoclonal antibody named Mitchga Subcutaneous Injection 60 mg Syringes. This breakthrough was specifically crafted to combat itching linked to atopic dermatitis, representing a remarkable advancement in medical science.

It is crucial to emphasize that this development marks a watershed moment in the field, as it signifies the first instance of an antibody drug effectively inhibiting IL-31 signaling. This is of profound significance because IL-31 is a neuroimmune cytokine intimately associated with pruritus and skin inflammation, particularly in the context of atopic dermatitis. The anti-IL-31 receptor functions by obstructing the binding of IL-31 to its receptor, ultimately thwarting the onset of itch and the development of skin inflammation, which are commonly encountered challenges in the management of atopic dermatitis. The introduction of such innovative treatments is a testament to the constant evolution of medical science, as it endeavors to enhance the quality of life for individuals affected by pruritus and related ailments. This paradigm-shifting advancement serves as a prime illustration of the dynamic and progressive nature of the pruritus therapeutic market, reflecting a fervent commitment to medical progress and patient well-being.

The pruritus therapeutic market is segmented:

1) Pruritus Therapeutic Market By Type: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Others Types

2) Pruritus Therapeutic Market By Disease Type: Atopic Dermatitis Or Eczema, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

3) Pruritus Therapeutic Market By Application: External Use, Oral, Injection

4) Pruritus Therapeutic Market By End Use: Hospitals, Clinics, Other Uses

Top Major Players

Allergan PLC

Astellas Pharma Inc.

Bristol-Myers Squibb Company

Cipla Inc.

Eli Lilly and Company

North America was the largest region in the pruritus therapeutic market in 2022.

The table of contents in TBRC’s pruritus therapeutic market report includes:

1. Executive Summary

2. Pruritus Therapeutic Market Characteristics

3. Pruritus Therapeutic Market Trends And Strategies

4. Pruritus Therapeutic Market – Macro Economic Scenario

5. Pruritus Therapeutic Market Size And Growth

……

26. Africa Pruritus Therapeutic Market

27. Pruritus Therapeutic Market Competitive Landscape And Company Profiles

28. Key Mergers And Acquisitions In The Pruritus Therapeutic Market

29. Pruritus Therapeutic Market Future Outlook and Potential Analysis

30. Appendix

Read Related Reports:

https://www.thebusinessresearchcompany.com/report/home-healthcare-global-market-report

https://www.thebusinessresearchcompany.com/report/healthcare-service-global-market-report

https://www.thebusinessresearchcompany.com/report/healthcare-nanotechnology-global-market-report

List Of Tables

Table 1: Global Historic Market Growth, 2017-2022, $ Billion
Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
Table 3: Global Pruritus Therapeutic Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 4: Global Pruritus Therapeutic Market, Segmentation By Disease Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
Table 5: Global Pruritus Therapeutic Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

….

Table 47: Allergan PLC Financial Performance
Table 48: Astellas Pharma Inc. Financial Performance
Table 49: Bristol-Myers Squibb Company Financial Performance
Table 50: Cipla Inc. Financial Performance
Table 51: Eli Lilly and Company Financial Performance

Learn About Us:

The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.

Contact Us:
The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: [email protected]

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model